Fariba Parmer
Corneal and Contact Management · Grapevine, TXNPI 1467621516
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,760 of the $25,501 with a category attached, or 69.6%. Bausch & Lomb Americas Inc. accounts for 76.3% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $11,378, 3.5 times the $3,249 reported in 2019. Among corneal and contact management clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $147.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$19K
- Shire North American Group Inc$3K
- Alcon$376
- Biotissue Holdings Inc.$361
- Sun Pharmaceutical Industries Inc.$354
- Harrow Eye, LLC$335
- plus $1K from 11 others
What the payments were for
- Speaking & faculty fees$17,76070%
- Travel & lodging$2,52810%
- Food & beverage$5,21320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 71 | $19,466 |
| Shire North American Group Inc | 4 | $3,110 |
| Alcon | 12 | $376 |
| Biotissue Holdings Inc. | 12 | $361 |
| Sun Pharmaceutical Industries Inc. | 16 | $354 |
| Harrow Eye, LLC | 9 | $335 |
| Tarsus Pharmaceuticals, Inc. | 7 | $326 |
| AbbVie(2 entities) | 11 | $292 |
| Novartis | 9 | $250 |
| Dompe US, Inc. | 8 | $233 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $201 |
| Oyster Point Pharma, Inc. | 3 | $53 |
| Rayner Intraocular Lenses Limited | 2 | $38 |
| Kala Pharmaceuticals, Inc. | 2 | $37 |
| Sight Sciences, Inc. | 1 | $32 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$20,631
- MIEBO$17,601
- BLINK NUTRITEARS$400
- TRYPTYR$128
- Tecnis IOL$125
- Tecnis Simplicity$125
- VERITAS Vision System$125
- XDEMVY$123
- VEVYE$110
How this compares
$25,501 in reported general payments places this provider in the 95th percentile of 103 corneal and contact management providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 23 | $1,306,218 |
| MieboPerfluorohexyloctane/Pf | 77 | $59,311 |
| RestasisCyclosporine | 39 | $52,000 |
| XiidraLifitegrast | 45 | $49,195 |
| XdemvyLotilaner | 25 | $46,991 |
| CequaCyclosporine | 16 | $17,050 |
| VevyeCyclosporine | 12 | $8,521 |
| Loteprednol Etabonate | 26 | $5,134 |
| Cyclosporine | 12 | $3,284 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 102 | $995 |
| Latanoprost | 40 | $394 |
| Timolol Maleate | 12 | $277 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $91 |
| Brimonidine Tartrate | 14 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $233 | $1,306,21823 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $19,466 | $108,506122 claims |
| AbbVieRestasis | $292 | $52,00039 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $326 | $46,99125 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $354 | $17,05016 claims |
| Harrow Eye, LLCVevye | $335 | $8,52112 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $24 | $5,13426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 103 corneal and contact management providers in Texas.
Other corneal and contact management in Grapevine
- Maurice WilsonConroe$362K
- Roberto SaenzSan Antonio$171K
- Vissett SunHouston$13K
- Napoleon LoveroHouston$12K
- Sairah MalikHouston$10K
- Darlene JonesPlano$9K
- Heriberto RamosCorpus Christi$9K
- Glenn EllisorKingwood$7K
- Danny MalonePlano$7K
- Leigh GreenWaco$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.